Drug Repurposing of ACT001 to Discover Novel Promising Sulfide Prodrugs with Improved Safety and Potent Activity for Neutrophil-Mediated Antifungal Immunotherapy
Neutrophil-mediated immunotherapy is a promising strategy for treating Candida albicans infection due to its potential in dealing with drug-resistant events. Our previous study found that ACT001 exhibited good antifungal immunotherapeutic activity by inhibiting PD-L1 expression in neutrophils, but its strong cytotoxicity and high BBB permeability hindered its antifungal application. To address these deficiencies, a series of novel sulfide derivatives were designed and synthesized based on a slow-release prodrug strategy. Among these derivatives, compound 16 exhibited stronger inhibition of PD-L1 expression, less cytotoxicity to neutrophils, and lower BBB permeability than ACT001. Compound 16 also significantly enhanced neutrophil-mediated antifungal immunity in C. albicans infected mice, with acceptable pharmacokinetic properties and good oral safety. Moreover, pharmacological mechanism studies demonstrated that ACT001 and compound 16 reduced PD-L1 expression in neutrophils by directly targeting STAT3. Briefly, this study provided a novel prototype compound 16 which exhibited great potential in neutrophil-mediated antifungal immunotherapy.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
---|---|
Enthalten in: |
Journal of medicinal chemistry - 67(2024), 7 vom: 11. Apr., Seite 5783-5799 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lu, Xiangran [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 12.04.2024 Date Revised 12.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1021/acs.jmedchem.3c02453 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370165209 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370165209 | ||
003 | DE-627 | ||
005 | 20240412233124.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240327s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1021/acs.jmedchem.3c02453 |2 doi | |
028 | 5 | 2 | |a pubmed24n1373.xml |
035 | |a (DE-627)NLM370165209 | ||
035 | |a (NLM)38526960 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lu, Xiangran |e verfasserin |4 aut | |
245 | 1 | 0 | |a Drug Repurposing of ACT001 to Discover Novel Promising Sulfide Prodrugs with Improved Safety and Potent Activity for Neutrophil-Mediated Antifungal Immunotherapy |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 12.04.2024 | ||
500 | |a Date Revised 12.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Neutrophil-mediated immunotherapy is a promising strategy for treating Candida albicans infection due to its potential in dealing with drug-resistant events. Our previous study found that ACT001 exhibited good antifungal immunotherapeutic activity by inhibiting PD-L1 expression in neutrophils, but its strong cytotoxicity and high BBB permeability hindered its antifungal application. To address these deficiencies, a series of novel sulfide derivatives were designed and synthesized based on a slow-release prodrug strategy. Among these derivatives, compound 16 exhibited stronger inhibition of PD-L1 expression, less cytotoxicity to neutrophils, and lower BBB permeability than ACT001. Compound 16 also significantly enhanced neutrophil-mediated antifungal immunity in C. albicans infected mice, with acceptable pharmacokinetic properties and good oral safety. Moreover, pharmacological mechanism studies demonstrated that ACT001 and compound 16 reduced PD-L1 expression in neutrophils by directly targeting STAT3. Briefly, this study provided a novel prototype compound 16 which exhibited great potential in neutrophil-mediated antifungal immunotherapy | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Antifungal Agents |2 NLM | |
650 | 7 | |a B7-H1 Antigen |2 NLM | |
650 | 7 | |a ACT001 |2 NLM | |
650 | 7 | |a Furans |2 NLM | |
700 | 1 | |a Wang, Rongrong |e verfasserin |4 aut | |
700 | 1 | |a Yu, Yao |e verfasserin |4 aut | |
700 | 1 | |a Wei, Jinlian |e verfasserin |4 aut | |
700 | 1 | |a Xu, Yixiang |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Luoyifan |e verfasserin |4 aut | |
700 | 1 | |a Mao, Fei |e verfasserin |4 aut | |
700 | 1 | |a Li, Jian |e verfasserin |4 aut | |
700 | 1 | |a Li, Xiaokang |e verfasserin |4 aut | |
700 | 1 | |a Jia, Xinming |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medicinal chemistry |d 1963 |g 67(2024), 7 vom: 11. Apr., Seite 5783-5799 |w (DE-627)NLM000006602 |x 1520-4804 |7 nnns |
773 | 1 | 8 | |g volume:67 |g year:2024 |g number:7 |g day:11 |g month:04 |g pages:5783-5799 |
856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.jmedchem.3c02453 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 67 |j 2024 |e 7 |b 11 |c 04 |h 5783-5799 |